Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case

Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 -- 48-week trial will enroll approximately 150 ...

Dyne commences Phase III HARMONIA trial for DM1 therapy

Dyne Therapeutics has initiated the Phase III HARMONIA trial to evaluate the efficacy, safety, and tolerability of zeleciment basivarsen (z-basivarsen, also called DYNE-101) in individuals diagnosed ...

Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 Stocks Investors Are Watching. Dyne Therapeutics saw its share prices jump by 11.81 percent on Tuesday to close at $19.78 apiece, after an ...
AZ Central

Inspect Point and Dyne Fire Protection Labs Launch Partnership to Bring Integrated Sprinkler Testing Workflow

TROY, NY, UNITED STATES, February 5, 2026 /EINPresswire.com/ — Inspect Point, the leading SaaS platform for fire and life safety inspection, testing, and compliance ...